CLINICAL TRIALS PROFILE FOR CEND-1
Clinical Trials for CEND-1
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03517176 ↗ | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | Completed | DrugCendR Inc. | Phase 1 | CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma |
| NCT05042128 ↗ | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Australasian Gastro-Intestinal Trials Group | Phase 2 | The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life. |
| NCT05042128 ↗ | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | University of Sydney | Phase 2 | The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life. |
| NCT05052567 ↗ | CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Cend Therapeutics Inc. | Phase 1/Phase 2 | The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population). |
| NCT05052567 ↗ | CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Phase 1/Phase 2 | The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population). |
| NCT05121038 ↗ | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab | Not yet recruiting | Cend Therapeutics Inc. | Phase 1/Phase 2 | This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers |
| NCT05121038 ↗ | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab | Not yet recruiting | Anup Kasi | Phase 1/Phase 2 | This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CEND-1
Condition Name
Clinical Trial Locations for CEND-1
Trials by Country
Clinical Trial Progress for CEND-1
Clinical Trial Phase
Clinical Trial Sponsors for CEND-1
Sponsor Name
